Recent Finacing
Recent Raise
Bluestar Genomics develops noninvasive blood-based cancer screening assays using cell-free DNA 5-hydroxymethylcytosine profiling and machine learning to detect multiple cancers, including an FDA breakthrough-designated pancreatic test.
